A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

Radical Interoperability: Let’s break down the barriers on health care information systems

by Dr. Douglas Rosendale, DO, FACOS, FACS, DO, FACOS, FACS Federal Chief Medical Interoperability Officer, Deloitte Consulting LLP

Maybe it’s because I spent my early career as a “cowboy surgeon” in Colorado, but I’ve always been a bit of a maverick when it comes to using technology to improve health care delivery and outcomes. I was chief of surgery at the Veterans Administration when I founded and chaired the Health IT Innovation Development program under the White House Office of Science and Technology Policy to develop radical,

Read more

Disruptive potential of genomics could prompt life sciences companies to accelerate deal-making

by Susan Dettmar, principal, US M&A consultative services leader, and Kushan Biswas, Life Sciences M&A senior manager, Deloitte Consulting LLP

The ability to transform genomic information into effective diagnostics and therapies might represent the future of medicine. This potential is inspiring a new era of deal-making among biopharmaceutical and genomics companies that want to achieve a leadership position in next-generation therapies.

Within the next 12-18 months, 85 percent of global life sciences firms expect to leverage genomics data—either purchased data or through partnerships,

Read more

Portfolio optimization could help medtech navigate a perfect storm

by Mark Fedro, principal, Deloitte Consulting LLP and Luis Hakim, senior manager, Deloitte Consulting LLP

Years of growth through acquisition has resulted in a number of large players in the medtech space. Many companies that didn’t appropriately integrate the acquired companies (or their products) are now finding it difficult to effectively manage their extensive and complex product portfolios, which could be restricting their margins and their ability to invest and innovate.

Read more

The future of drug rebates: Are they to be or not to be?

by George Van Antwerp, Managing Director, Deloitte Consulting LLP

Nearly half of all Americans (49 percent) have at least one prescription drug, and 12 percent of the population has five or more, according to 2017 data from the Centers for Drug Control and Prevention (CDC). In 2016, $329 billion was spent on prescription drugs—an increase of nearly 30 percent from 2010.1

With so much money at stake,

Read more

The five Cs of disruption

by Pete Micca, Partner, Deloitte & Touche LLP

What’s shaping the future of health tech investment?

 

Health care technology investment in 2017 appeared to be all about convergence. In fact, there were no health tech IPOs at all that year.1 The focus seemed to be squarely on expanding industry footprints to gain economies of scale and more control over the continuum of health services.

Read more

Winning the patient-centric race

by Chris Zant, Principal, Deloitte Digital, Deloitte Consulting LLP

Digital technology and the pharma-patient relationship

The evolution of digital technology in health care has been truly breathtaking. Once a few devices and apps in the clinical setting seemed revolutionary. We now see a future with a full-scale digital technology uptake with streamlined reimbursement and back office functions as well as ROI measurement.

Read more